Skip to content

Piloting Pathways With Lung Cancer Patients

Piloting Pathways, a Hope-enhancing Intervention to Address Activity and Role Function in Metastatic Lung Cancer Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04161157
Enrollment
53
Registered
2019-11-13
Start date
2020-01-13
Completion date
2022-08-03
Last updated
2023-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Lung Cancer

Brief summary

The purpose of this research is to determine the feasibility of a new supportive intervention, called Pathways, for patients with advanced stage and metastatic lung cancer.

Detailed description

In this study, investigators will first test the Pathways procedures with 6 patients to identify any improvements that need to be made. Then, investigators will test the feasibility of the Pathways intervention with 20 patients who are undergoing cancer treatment for advanced stage or metastatic lung cancer. Pathways is designed to help patients set and pursue personal goals during lung cancer treatment. In this study, investigators want to see if they can recruit patients with lung cancer who are being treated at the University of Kentucky Markey Cancer Center to participate in the Pathways intervention.

Interventions

BEHAVIORALPathways

Goal-setting intervention to help patients identify personal values, value-consistent goals, and ways to pursue goals and address goal obstacles. Although potential refinements may occur based on aim 1 (refining procedures and content with 6 patients), Pathways is designed to consist primarily of 2 in-person sessions (\ 30-60 minutes) delivered when patients are in clinic for cancer treatment, with supporting phone calls and contact in between sessions.

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Laurie McLouth
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* new or recurrent stage IIIB, stage IIIC or stage IV non-small cell lung cancer (NSCLC) or extensive stage SCLC * 18 years of age or older * ECOG PS 0-2/Karnofsky 60-100 * 3 to 12 weeks into active cancer treatment

Exclusion criteria

* unstable brain metastases * cognitive or psychiatric condition for which participating would be inappropriate * unable to speak and read English

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of Enrollment: Percentage of Eligible and Approached Patients Who Agree to Participate9 monthsPercentage of eligible and approached patients who agree to participate
Acceptability: Ratings9 monthsMean acceptability ratings on individual items of acceptability developed by study team (e.g., convenience of the intervention, helpfulness of the intervention, relevance of the intervention; scores of at least 7/10 on each item, possible range = 1-10, higher scores indicate higher acceptability).

Secondary

MeasureTime frameDescription
Purpose - PROMIS Meaning and Purpose 4a9 monthsBrief measure assessing one's sense of purpose and that there are reasons for living; 4 items responded to on a scale of 1 = not at all to 5 = very much (possible raw score range = 4 - 20). Higher scores indicate greater meaning and purpose.
PROMIS Satisfaction With Participation in Social Roles - Short Form 8a9 monthsBrief measure of satisfaction with ability and participation in activities and roles (e.g., work at home, regular personal and household responsibilities, do things for family) Higher scores indicate more satisfaction with participation. Raw scores range from 8 to 40. 8 items are responded to on a scale of 1 = not at all to 5 = very much.
Lung Cancer Stigma - Lung Cancer Stigma Inventory (Hamann)9 monthsmeasure of lung cancer stigma. 25 items making up three subscales (perceived stigma, internalized stigma, and constrained disclosure). Items are responded to on a scale of 1 = not at all to 5 = extremely. Items are summed, with a higher score indicating greater lung cancer stigma/worse outcome (possible total score range = 25-125) . Clinical cutoff of a total score of 37.5 is suggested in literature as significant levels of stigma.
Distress - PROMIS Depression Short Form 6a9 monthsBrief measure assessing sense of worthlessness, helplessness, depression, etc. 6 items are responded to on a scale of 1 = never to 5 = always (possible raw scores range from 6-30). Higher scores indicate greater distress.
Hope - State Hope Scale (Snyder)9 monthsBrief measure of agency and pathways thinking. 6 items responded to on a scale of 1 = definitely false to 8 = definitely true. Items are summed for a total score (possible range = 6 - 48). Higher scores indicate higher hope.

Countries

United States

Participant flow

Participants by arm

ArmCount
Pathways
Pathways is designed to help patients identify and pursue values-based goals and address potential goal obstacles, including lung cancer stigma. Pathways: Goal-setting intervention to help patients identify personal values, value-consistent goals, and ways to pursue goals and address goal obstacles. Although potential refinements may occur based on aim 1 (refining procedures and content with 6 patients), Pathways is designed to consist primarily of 2 in-person sessions (\ 30-60 minutes) delivered when patients are in clinic for cancer treatment, with supporting phone calls and contact in between sessions.
52
Total52

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyDeath3
Overall StudyIneligible2
Overall StudyLost to Follow-up4
Overall StudyWithdrawal by Subject4

Baseline characteristics

CharacteristicPathways
Age, Continuous61.4 years
STANDARD_DEVIATION 10.7
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
52 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
7 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
Race (NIH/OMB)
White
44 Participants
Region of Enrollment
United States
52 participants
Sex: Female, Male
Female
31 Participants
Sex: Female, Male
Male
21 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
3 / 53
other
Total, other adverse events
0 / 53
serious
Total, serious adverse events
0 / 53

Outcome results

Primary

Acceptability: Ratings

Mean acceptability ratings on individual items of acceptability developed by study team (e.g., convenience of the intervention, helpfulness of the intervention, relevance of the intervention; scores of at least 7/10 on each item, possible range = 1-10, higher scores indicate higher acceptability).

Time frame: 9 months

Population: 1 participant skipped this measure so overall number is 39 instead of 40

ArmMeasureGroupValue (MEAN)Dispersion
PathwaysAcceptability: RatingsConvenience of intervention8.79 score on a scaleStandard Deviation 1.17
PathwaysAcceptability: RatingsRelevance of intervention8.46 score on a scaleStandard Deviation 1.67
PathwaysAcceptability: RatingsHelpfulness of intervention8.54 score on a scaleStandard Deviation 1.55
Primary

Feasibility of Enrollment: Percentage of Eligible and Approached Patients Who Agree to Participate

Percentage of eligible and approached patients who agree to participate

Time frame: 9 months

Population: 98 potentially eligible people were approached, of whom 53 agreed to participate.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
PathwaysFeasibility of Enrollment: Percentage of Eligible and Approached Patients Who Agree to Participate53 Participants
Secondary

Distress - PROMIS Depression Short Form 6a

Brief measure assessing sense of worthlessness, helplessness, depression, etc. 6 items are responded to on a scale of 1 = never to 5 = always (possible raw scores range from 6-30). Higher scores indicate greater distress.

Time frame: 9 months

Population: 1 participant skipped this measure so overall number is 39 instead of 40

ArmMeasureValue (MEAN)Dispersion
PathwaysDistress - PROMIS Depression Short Form 6a11.3 total raw score on a scaleStandard Deviation 5.87
Secondary

Hope - State Hope Scale (Snyder)

Brief measure of agency and pathways thinking. 6 items responded to on a scale of 1 = definitely false to 8 = definitely true. Items are summed for a total score (possible range = 6 - 48). Higher scores indicate higher hope.

Time frame: 9 months

ArmMeasureValue (MEAN)Dispersion
PathwaysHope - State Hope Scale (Snyder)31.3 total score on a scaleStandard Deviation 7.9
Secondary

Lung Cancer Stigma - Lung Cancer Stigma Inventory (Hamann)

measure of lung cancer stigma. 25 items making up three subscales (perceived stigma, internalized stigma, and constrained disclosure). Items are responded to on a scale of 1 = not at all to 5 = extremely. Items are summed, with a higher score indicating greater lung cancer stigma/worse outcome (possible total score range = 25-125) . Clinical cutoff of a total score of 37.5 is suggested in literature as significant levels of stigma.

Time frame: 9 months

ArmMeasureValue (MEAN)Dispersion
PathwaysLung Cancer Stigma - Lung Cancer Stigma Inventory (Hamann)52 total score on a scaleStandard Deviation 15.7
Secondary

PROMIS Satisfaction With Participation in Social Roles - Short Form 8a

Brief measure of satisfaction with ability and participation in activities and roles (e.g., work at home, regular personal and household responsibilities, do things for family) Higher scores indicate more satisfaction with participation. Raw scores range from 8 to 40. 8 items are responded to on a scale of 1 = not at all to 5 = very much.

Time frame: 9 months

ArmMeasureValue (MEAN)Dispersion
PathwaysPROMIS Satisfaction With Participation in Social Roles - Short Form 8a21.8 score on a scaleStandard Deviation 9.54
Secondary

Purpose - PROMIS Meaning and Purpose 4a

Brief measure assessing one's sense of purpose and that there are reasons for living; 4 items responded to on a scale of 1 = not at all to 5 = very much (possible raw score range = 4 - 20). Higher scores indicate greater meaning and purpose.

Time frame: 9 months

Population: 1 participant skipped this measure so overall number is 39 instead of 40

ArmMeasureValue (MEAN)Dispersion
PathwaysPurpose - PROMIS Meaning and Purpose 4a16.4 total raw score on a scaleStandard Deviation 3.7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026